STOCK TITAN

Hologic Inc - HOLX STOCK NEWS

Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.

Hologic Inc (HOLX) delivers innovative healthcare solutions through diagnostic imaging systems and surgical technologies focused on women’s health. This dedicated news hub provides investors and industry professionals with essential updates directly from the company and verified sources.

Access timely Hologic press releases, earnings reports, and strategic announcements in one centralized location. Track developments across key business segments including diagnostic systems, breast health technologies, and minimally invasive surgical solutions. Our curated feed ensures you never miss regulatory filings, product approvals, or partnership announcements impacting this medical technology leader.

This resource serves as your primary source for monitoring Hologic’s advancements in healthcare diagnostics and operational milestones. Content is rigorously verified to maintain factual accuracy while avoiding speculative analysis. Bookmark this page for efficient tracking of HOLX’s progress in developing technologies that enhance clinical decision-making worldwide.

Rhea-AI Summary
Company XYZ, a leading women's health company (Ticker: XYZ), urges women to openly discuss their health issues with their doctors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) reported preliminary revenue results for its first fiscal quarter ended December 30, 2023, totaling approximately $1,013.1 million, exceeding the most recent revenue guidance range of $960 to $985 million. Despite a decrease compared to the prior year period, the company achieved 5.2% organic constant currency revenue growth, surpassing expectations. The company's Chairman, President, and CEO, Steve MacMillan, emphasized strong organic revenue performance, estimating over 9% growth in total company organic revenue excluding COVID-19. The preliminary results highlight divisional revenue changes, with Breast Health showing significant growth of 13.0% and GYN Surgical growing by 5.3%. Hologic expects non-GAAP diluted earnings per share (EPS) to be towards the high-end of the guidance range of $0.92 to $0.97 and plans to provide full financial results on February 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
-
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) will release its first quarter fiscal 2024 financial results on February 1, after the market closes. Management will host a conference call at 4:30 p.m. Eastern Time. Interested participants can join the call by dialing (888) 394-8218 (US and Canada) or +1 (773) 305-6853 (international callers) with access code 5909239. A live and webcast replay will be available on the Company’s website at https://investors.hologic.com for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
conferences
-
Rhea-AI Summary
KKR and Hologic, Inc. (Nasdaq: HOLX) have announced the establishment of a new platform named Maverix Medical, focused on developing and acquiring innovative technologies and commercial operations within the lung cancer disease category. The platform will be managed by Ajax Health under the leadership of Duke Rohlen. KKR and Hologic, Inc. will contribute existing portfolio company Serpex Medical to the platform, which develops innovative steerable technology for lung tissue biopsy or therapy delivery. This strategic partnership aims to develop, advance, and bring to market differentiated devices and diagnostics for lung cancer patients, aligning with Hologic's leadership in diagnostic innovation and early cancer detection. KKR is investing in Maverix through its Health Care Strategic Growth strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary
Hologic, Inc. (HOLX) to Showcase Next-Generation AI Solutions for Cancer Detection and Radiologist Workflow at RSNA 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
AI
Rhea-AI Summary
Hologic, Inc. (HOLX) to Present at Evercore ISI HealthCONx Conference on November 28, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
conferences
-
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) reported Q4'23 revenue of $945.3M, GAAP Diluted EPS of $0.37, and Non-GAAP Diluted EPS of $0.89. Total Company Organic Revenue Growth, excluding COVID-19, was 16.7% in constant currency. Despite a decrease in revenue due to lower sales of COVID-19 assays, total organic revenue grew 17.5%. The company plans to enter into a $500M accelerated share repurchase agreement and expects strong performance in fiscal 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
-
Rhea-AI Summary
Hologic partners with AAGL and Inovus Medical to provide hysteroscopy skills training for OB-GYN residents
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
Rhea-AI Summary
Hologic, Inc. (HOLX) to release Q4 2023 financial results on November 9th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
Hologic Inc

Nasdaq:HOLX

HOLX Rankings

HOLX Stock Data

13.23B
222.47M
0.85%
105.3%
1.98%
Medical Instruments & Supplies
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States
MARLBOROUGH